The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.
A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Gene therapy simplified: what is it and how does it work?
Gene therapies are being developed at a rapid rate. Although there are currently no FDA-approved or interventional gene therapies for FXS, the future has never looked brighter for treating the root cause of FXS!
A Message from Harmony Biosciences Before the 19th NFXF International Fragile X Conference
Here's a message from our friends at Harmony Biosciences in advance of the 19th NFXF International Fragile X Conference.